The chapter explores whether high-income countries are ready for the first disease-modifying Alzheimer’s disease (AD) treatment, approved in the USA in February 2021. It looks at the capacity to provide diagnostic services relative to the expected demand, institutional preparedness, and potential solutions to overcome capacity constraints. Wait times are projected to differ substantially. Initial average wait times range from 5 months in Germany to 28 months in Canada. In France, Canada, and Taiwan, we project it will take over a decade to clear the backlog of prevalent cases and to make a treatment accessible with little delay, because of scarcity of dementia specialists, and aggravated by the lack of financial and structural plannin. Potential solutions include broadening the dementia workforce by integration of primary care clinicians and other specialists, care models that leverage specialist time, and telecare-supported models. Better diagnostic technology to detect cognitive decline and the AD pathology in primary care settings and predictive models to triage patients show potential to improve access.